Article
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2025
De Giglio Andrea, De Biase Dario, Favorito Valentina, Maloberti Thais, Di Federico Alessandro, Zacchini Federico, Venturi Giulia, Parisi Claudia, Gustavo Dall'Olio Filippo, Ricciotti Ilaria, Gagliano Ambrogio, Melotti Barbara, Sperandi Francesca, Altimari Annalisa, Gruppioni Elisa, Tallini Giovanni, Gelsomino Francesco, Montanaro Lorenzo, Ardizzoni Andrea
Abstract excerpt
BACKGROUND: The upfront treatment of non-oncogene-addicted NSCLC relies on immunotherapy alone (ICI) or in combination with chemotherapy (CT-ICI). Genomic aberrations such as KRAS, TP53, KEAP1, SMARCA4, or STK11 may impact survival outcomes. METHODS: We performed an observational study of 145 patients treated with first-line IO or CT-ICI for advanced non-squamous (nsq) NSCLC at our institution tested with an...
Topics
Join the communities discussing this publication.